Date published: 2026-9-5

1-800-457-3801

SCBT Portrait Logo
Seach Input

TGFβ2 CRISPR/Cas9 KO Plasmid (h): sc-400496

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • TGFβ2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TGFβ2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TGFβ2 Antibody (H-6): sc-374659
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    TGFβ2 CRISPR/Cas9 KO Plasmid (h)

    sc-400496
    20 µg
    $397.00

    Overview

    TGFB2 encodes transforming growth factor beta 2 (TGFβ2), a secreted cytokine that signals through TGF-β receptor serine/threonine kinases to activate SMAD2/3-dependent transcription and intersect with non-canonical pathways such as MAPK, PI3K/AKT, and Rho-like GTPases. TGFβ2 is a key regulator of extracellular matrix remodeling, epithelial–mesenchymal transition, immune modulation, and cell fate decisions during development and tissue homeostasis. Dysregulated TGFB2 signaling has been associated with fibrosis, aberrant wound repair, and tumor–stroma interactions, making it relevant for studies of microenvironment-driven phenotypes. In human cell models, perturbing TGFB2 supports mechanistic analysis of TGF-β pathway dynamics and downstream gene regulatory programs.

    TGFβ2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TGFB2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TGFB2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TGFB2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TGFβ2 protein expression.

    This CRISPR knockout system enables efficient generation of TGFB2-deficient cell models for investigation of TGFβ2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting TGFB2 exon(s) critical for TGFβ2 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple TGFB2 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by TGFβ2 CRISPR/Cas9 KO Plasmid (h) and TGFβ2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TGFB2 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by TGFβ2 HDR Plasmid (h) and TGFβ2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TGFB2 homology arms to support homology-directed repair at defined TGFB2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.